A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research
Open Access
- 1 April 2021
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 95, 102174
Abstract
No abstract availableKeywords
This publication has 75 references indexed in Scilit:
- Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypesBMC Cancer, 2013
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialThe Lancet, 2011
- Microsatellite instability in colorectal cancer—the stable evidenceNature Reviews Clinical Oncology, 2010
- Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancerBritish Journal of Cancer, 2009
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Deficient mismatch repair system in patients with sporadic advanced colorectal cancerBritish Journal of Cancer, 2009
- Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell linesBritish Journal of Cancer, 2008
- Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS TrialJournal of Clinical Oncology, 2008
- The third dimension bridges the gap between cell culture and live tissueNature Reviews Molecular Cell Biology, 2007
- CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerNature Genetics, 2006